Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2022.1987220 ◽

2021 ◽

Author(s):

J Aguilar-Serra ◽

V Gimeno-Ballester ◽

A Pastor-Clerigues ◽

J Milara ◽

C Trigo-Vicente ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

Egfr Mutated ◽

Download Full-text

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

PharmacoEconomics ◽

10.1007/s40273-021-01022-9 ◽

2021 ◽

Author(s):

Yong-Jin Kim ◽

Mark Oremus ◽

Helen H. Chen ◽

Thomas McFarlane ◽

Danielle Fearon ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China

Journal of Medical Economics ◽

10.1080/13696998.2019.1570221 ◽

2019 ◽

Vol 22 (4) ◽

pp. 344-349 ◽

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

David Hutton ◽

Qiu Li

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Frontiers in Oncology ◽

10.3389/fonc.2020.01649 ◽

2020 ◽

Vol 10 ◽

Author(s):

Huabin Hu ◽

Longjiang She ◽

Mengting Liao ◽

Yin Shi ◽

Linli Yao ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

First Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER

Value in Health ◽

10.1016/j.jval.2018.09.016 ◽

2018 ◽

Vol 21 ◽

pp. S3

Author(s):

M.S. Holleman ◽

M.J. Al ◽

C.A. Uyl-de Groot

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

PCN36 Cost-Effectiveness Analysis of Pembrolizumab Versus Nivolumab As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer in Germany

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.086 ◽

2020 ◽

Vol 22 ◽

pp. S11

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-Effectiveness Analysis of Afatinib Versus Gefitinib in Egfr-Mutated Population with Advanced Non-Small-Cell Lung Cancer in France

Value in Health ◽

10.1016/j.jval.2017.08.236 ◽

2017 ◽

Vol 20 (9) ◽

pp. A439

Author(s):

G de Pouvourville ◽

L Luciani ◽

K Le Lay ◽

P PO ◽

J Bennouna ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

Download Full-text

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Management and Research ◽

10.2147/cmar.s293983 ◽

2021 ◽

Vol Volume 13 ◽

pp. 4263-4270

Author(s):

Longfeng Zhang ◽

Na Li ◽

Maobai Liu ◽

Bin Zheng ◽

Zhijuan Wu ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review

PharmacoEconomics ◽

10.1007/s40273-021-01089-4 ◽

2021 ◽

Author(s):

Thitima Kongnakorn ◽

Grammati Sarri ◽

Andreas Freitag ◽

Kinga Marczell ◽

Paulina Kazmierska ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Literature Review ◽

Small Cell Lung Cancer ◽

Systematic Literature Review ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness analysis of endoscopic ultrasound as a first-line staging tool for patients with non-small-cell lung cancer

Endoscopy ◽

10.1055/s-0031-1292140 ◽

2011 ◽

Vol 43 (S 03) ◽

Author(s):

L Lai

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Endoscopic Ultrasound ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

PCN37 Cost-Effectiveness Analysis of Pembrolizumab Versus Nivolumab As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer in France

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.087 ◽

2020 ◽

Vol 22 ◽

pp. S11

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text